Objective: A dual-isotope imaging protocol using 99mTc-labeled red blood cells with 111In
capromab pendetide monoclonal antibody imaging for detecting and localizing nodal …

Objectives. No standard noninvasive diagnostic test reliably differentiates patients with
organ-confined prostate cancer from those with lymph node metastases. The ability of a …

BACKGROUND Optimum therapy for prostate carcinoma patients requires accurate staging,
but computed tomography (CT) and magnetic resonance imaging (MRI) have limitations as …

Purpose: To determine the diagnostic performance of In-111 capromab pendetide single
photon emission computed tomography/computed tomography (SPECT/CT), in the prostate …

The ability to label tissue-specific antibodies has long been of interest for improving
detection and guidance for therapeutic applications. The most studied target for prostate …

To provide appropriate therapy for prostate cancer, accurate stag ing of the patient's disease
is essential. Determination of tumor size, location, periprostatic extension and metastatic …

Purpose To preliminarily evaluate the potential for an improvement in diagnostic
performance by a combined interpretation of In-111 capromab pendetide single photon …

PURPOSE: We compared the results of a preoperative 111In-capromab pendetide scan co-
registered with computerized tomography with pathological findings in the surgically excised …

This study evaluated the utility of In-111 capromab pendetide imaging to detect prostate
cancer metastases or local recurrence. The specific goal was to identify clinical factors such …

Purpose Capromab pendetide (ProstaScint) is an indium In 111 ((111) In)-labeled
monoclonal antibody to prostate-specific membrane antigen (PSMA) used to image prostate …